公开(公告)号：US20250154241A1

公开(公告)日：2025-05-15

申请号：US19022014

申请日：2025-01-15

Applicant: AMGEN INC.

Inventor： Michael R. Comeau ,  James F. Smothers ,  Bo-Rin P. Yoon ,  Christopher Mehlin

IPC: C07K16/24 ,  A61K39/00 ,  A61K39/395

Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.

公开(公告)号：US11059895B2

公开(公告)日：2021-07-13

申请号：US16242278

申请日：2019-01-08

Applicant: Amgen Inc.

Inventor： Dirk E. Smith ,  Ian Foltz ,  Chadwick T. King ,  Ai Ching Lim ,  Rutilio Clark ,  Michael R. Comeau ,  Randal R. Ketchem ,  Donghui Shi ,  Xiaoshan Min ,  Zhulun Wang

IPC: C07K16/28 ,  C07K16/24 ,  A61K39/00 ,  C12N15/11

Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

公开(公告)号：US20170114140A1

公开(公告)日：2017-04-27

申请号：US15341870

申请日：2016-11-02

Applicant: KIRIN-AMGEN, INC.

Inventor： Alison L. Budelsky ,  Michael R. Comeau ,  Joel E. Tocker

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/76

Abstract: The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. Antagonists of the IL-17RA-IL-17RB heteromeric receptor complex are disclosed, as well as various methods of use.

公开(公告)号：US20170081668A1

公开(公告)日：2017-03-23

申请号：US15285949

申请日：2016-10-05

Applicant: Amgen Inc.

Inventor： Michael R. Comeau ,  David Fitzpatrick

IPC: C12N15/113 ,  A61K31/7088 ,  A61K39/395 ,  C07K16/24 ,  A61K45/06

CPC classification number: C12N15/1136 ,  A61K31/7088 ,  A61K38/1793 ,  A61K38/2046 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/24 ,  C12N2310/11 ,  C12N2310/14

Abstract: The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine.